Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 years or older at the time of signing informed consent~* Body mass index (BMI) equal to or above 30.0 kg/m\^2 or equal to or above 27.0 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* HbA1c equal to or above 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* History of type 1 or type 2 diabetes mellitus~* A self-reported change in body weight of more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
- Liraglutide (Type: ACTIVE_COMPARATOR): Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
- Placebo (liraglutide) (Type: PLACEBO_COMPARATOR): Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity

Based on this trial design, predict the completion outcome and termination type (if applicable).